Elo Mutual Pension Insurance Co Trims Stock Position in Stryker Co. (NYSE:SYK)

Elo Mutual Pension Insurance Co decreased its stake in shares of Stryker Co. (NYSE:SYK) by 3.9% during the fourth quarter, HoldingsChannel reports. The firm owned 31,298 shares of the medical technology company’s stock after selling 1,287 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Stryker were worth $11,269,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Stryker in the 4th quarter valued at approximately $25,000. Dunhill Financial LLC grew its position in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the period. Rakuten Securities Inc. increased its stake in shares of Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new position in Stryker during the 4th quarter valued at about $30,000. Finally, BankPlus Trust Department bought a new stake in Stryker during the fourth quarter worth about $33,000. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

NYSE SYK opened at $367.34 on Thursday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a market cap of $140.17 billion, a price-to-earnings ratio of 47.34, a PEG ratio of 2.93 and a beta of 0.95. The company’s 50 day moving average is $384.74 and its two-hundred day moving average is $374.29.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business posted $3.46 EPS. As a group, research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insider Buying and Selling

In other news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

SYK has been the subject of several recent research reports. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $370.00 to $445.00 in a report on Monday, December 2nd. JMP Securities reissued a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Argus set a $450.00 price target on Stryker in a research report on Monday, February 3rd. Barclays increased their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Finally, Citigroup reaffirmed a “buy” rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $421.90.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.